search
Back to results

The SaVe Project-Sarcopenia and Vertigo in Aging Patients With Colorectal Cancer (SaVe)

Primary Purpose

Colorectal Cancer, Oncologic Complications, Comprehensive Geriatric Assessment

Status
Not yet recruiting
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Targeted specialized physical group-based exercise and Comprehensive Geriatric Assessement
Sponsored by
Rigshospitalet, Denmark
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Colorectal Cancer

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Meet the criteria of the oncological departments of receiving adjuvant chemotherapy or first line palliative chemotherapy for colorectal cancer ≥65 years of age at the time of signing the informed consent form Able to speak and read Danish, and to provide a signed informed consent form Have an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2 Exclusion Criteria: Other malignant disease except from basal cell carcinoma and carcinoma in situ cervices uteri within five years Have recieved chemotherapy within five years Severe physical disability that hinders physical exercise Dementia, psychotic disorders, or other cognitive diseases or conditions that hinder participation in a clinical exercise-based trial Inability to sign informed content Patients who have had a consultation in the geriatric outpatient clinic within the past six months

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    Intervention group

    Usual care group

    Arm Description

    Patients in the intervention groups will receive adjuvant or first line palliative chemotherapy (for metastatic disease). In addition, all patients will undergo three months' targeted specialized physical group-based exercise and Comprehensive Geriatric Assessment with corresponding interventions

    Patients in the usual care groups will receive standard treatment with adjuvant or first line palliative chemotherapy (for metastatic disease). If the patients have other health complaints, these will, as current standard procedure, be treated by oncologist or by referral to general practitioner

    Outcomes

    Primary Outcome Measures

    Dynamic Gait Index (DGI)
    Between-group difference in change in walking balance assessed with Dynamic Gait Index (DGI)

    Secondary Outcome Measures

    Falls
    Self-reported falls
    Hospital contacts due to falls
    Hospital contacts due to falls
    Balance disabilities/dizziness
    Changes in self-perceived balance disabilities/dizziness using the patient reported outcome measure Dizziness Handicap Inventory (DHI)
    Fear of falling
    Changes in fear of falling using the patient reported outcome measure Falls Efficacy Scale International (FES-I)
    Health related quality of life
    Changes in health related quality of life using the patient reported outcome measure EORTC QLQ-C30
    Peripheral nerve function
    Changes in peripheral nerve function using biothesiometer
    Autonomic function
    Changes in autonomic function using Vagus device
    Chemotherapy induced peripheral neuropathy
    Severity of chemotherapy induced peripheral neuropathy using the patient reported outcome measure EORTC QLQ-CIPN-20
    Muscle strength
    Changes in muscle strength using HUR Leg Press Rehab performance recorder, handgrip test and 30 second chair stand test
    Body composition
    Changes in body composition using DXA

    Full Information

    First Posted
    January 16, 2023
    Last Updated
    January 25, 2023
    Sponsor
    Rigshospitalet, Denmark
    Collaborators
    Copenhagen University Hospital - Rigshospitalet, Department of Occupational Therapy and Physiotherapy, Copenhagen University Hospital - Herlev and Gentofte Hospital, Department of Medicine, Copenhagen University Hospital - Herlev and Gentofte Hospital, Department of Oncology, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Odense University Hospital, Department of Geriatric Medicine, Copenhagen University Hospital - Amager and Hvidovre Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05710809
    Brief Title
    The SaVe Project-Sarcopenia and Vertigo in Aging Patients With Colorectal Cancer
    Acronym
    SaVe
    Official Title
    The SaVe Project-Sarcopenia and Vertigo in Aging Patients With Colorectal Cancer
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    February 2023 (Anticipated)
    Primary Completion Date
    July 2025 (Anticipated)
    Study Completion Date
    January 2026 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Rigshospitalet, Denmark
    Collaborators
    Copenhagen University Hospital - Rigshospitalet, Department of Occupational Therapy and Physiotherapy, Copenhagen University Hospital - Herlev and Gentofte Hospital, Department of Medicine, Copenhagen University Hospital - Herlev and Gentofte Hospital, Department of Oncology, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Odense University Hospital, Department of Geriatric Medicine, Copenhagen University Hospital - Amager and Hvidovre Hospital

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The goal of this clinical trial is to learn about the cause of dizziness and decline in walking ability in in older adults ≥65 years during chemotherapy treatment for colorectal cancer. Another goal is to investigate if a comprehensive geriatric assessment and three months' specialized physical group-based exercise three times/week can counteract muscle weakness, vertigo, instability, impaired walking balance, and neuropathy
    Detailed Description
    Frequent adverse effects of chemotherapy in older adults are nausea and fatigue, but our research group have discovered a problem with many also suffering from sarcopenia, vertigo, dizziness, and peripheral neuropathy (CIPN) leading to balance and walking impairments causing increased risk of falls. Moreover, these symptoms are often underreported with inadequate awareness among health professionals leading to deficient focus on the need for targeted rehabilitation. A comprehensive geriatric assessment (CGA) can increase the number of frail, older patients completing chemotherapy and CGA-based interventions can decrease chemotherapy toxicity and improve health-related quality of life (HRQoL). Physical exercise has been shown to reduce muscle weakness, vertigo, dizziness, and impaired balance among older adults requiring limited resources. Therefore, this project aims to investigate the effectiveness of CGA and physical exercise to counteract muscle weakness, vertigo, instability, and impaired walking balance, during chemotherapy and to investigate the interaction between vertigo, postural stability and walking performance, and neuropathy and the prevalence of sarcopenia. The activities of specialized physical exercise planned in this intervention will, as hypothesized, result in a change in muscle strength, walking balance, self-perceived balance disabilities/dizziness, and fear of falling along with changes in peripheral nerve function and autonomic function and severity of CIPN which are the outcomes of this study. Accordingly, expectations are that this intervention will affect the HRQoL among older cancer patients with vertigo and walking impairments and reduce the number of falls and hospital admissions leading to a socioeconomic benefit.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Colorectal Cancer, Oncologic Complications, Comprehensive Geriatric Assessment, Vestibular Rehabilitation, Geriatric Oncology, Sarcopenia, Vertigo, Cancer, Rehabilitation, Exercise, Geriatric, Elderly, Frail, Older Adults, Chemotherapy, Chemotherapy-induced Peripheral Neuropathy, Resistance Training, Balance Training, Postural Stability, Pragmatic Trial, Personal Medicine, Individualised

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    InvestigatorOutcomes Assessor
    Masking Description
    Investigator = Statistician
    Allocation
    Randomized
    Enrollment
    150 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Intervention group
    Arm Type
    Experimental
    Arm Description
    Patients in the intervention groups will receive adjuvant or first line palliative chemotherapy (for metastatic disease). In addition, all patients will undergo three months' targeted specialized physical group-based exercise and Comprehensive Geriatric Assessment with corresponding interventions
    Arm Title
    Usual care group
    Arm Type
    No Intervention
    Arm Description
    Patients in the usual care groups will receive standard treatment with adjuvant or first line palliative chemotherapy (for metastatic disease). If the patients have other health complaints, these will, as current standard procedure, be treated by oncologist or by referral to general practitioner
    Intervention Type
    Other
    Intervention Name(s)
    Targeted specialized physical group-based exercise and Comprehensive Geriatric Assessement
    Intervention Description
    Vestibular rehabilitation, balance- and progressive resistance training for three months' three times/week and Comprehensive Geriatric Assessement including corresponding interventions
    Primary Outcome Measure Information:
    Title
    Dynamic Gait Index (DGI)
    Description
    Between-group difference in change in walking balance assessed with Dynamic Gait Index (DGI)
    Time Frame
    Three months
    Secondary Outcome Measure Information:
    Title
    Falls
    Description
    Self-reported falls
    Time Frame
    Baseline, three and six months
    Title
    Hospital contacts due to falls
    Description
    Hospital contacts due to falls
    Time Frame
    Baseline, three and six months
    Title
    Balance disabilities/dizziness
    Description
    Changes in self-perceived balance disabilities/dizziness using the patient reported outcome measure Dizziness Handicap Inventory (DHI)
    Time Frame
    Baseline, three and six months
    Title
    Fear of falling
    Description
    Changes in fear of falling using the patient reported outcome measure Falls Efficacy Scale International (FES-I)
    Time Frame
    Baseline, three and six months
    Title
    Health related quality of life
    Description
    Changes in health related quality of life using the patient reported outcome measure EORTC QLQ-C30
    Time Frame
    Baseline, three and six months
    Title
    Peripheral nerve function
    Description
    Changes in peripheral nerve function using biothesiometer
    Time Frame
    Baseline, three and six months
    Title
    Autonomic function
    Description
    Changes in autonomic function using Vagus device
    Time Frame
    Baseline, three and six months
    Title
    Chemotherapy induced peripheral neuropathy
    Description
    Severity of chemotherapy induced peripheral neuropathy using the patient reported outcome measure EORTC QLQ-CIPN-20
    Time Frame
    Baseline, three and six months
    Title
    Muscle strength
    Description
    Changes in muscle strength using HUR Leg Press Rehab performance recorder, handgrip test and 30 second chair stand test
    Time Frame
    Baseline, three and six months
    Title
    Body composition
    Description
    Changes in body composition using DXA
    Time Frame
    Baseline, three and six months
    Other Pre-specified Outcome Measures:
    Title
    Walking speed
    Description
    Changes in walking speed using 10 meter walk test
    Time Frame
    Baseline, three and six months
    Title
    Postural control
    Description
    Changes in postural control (standing balance) using HUR SmartBalance platform
    Time Frame
    Baseline, three and six months
    Title
    Vestibular function
    Description
    Changes in peripheral vestibular function using Video Head Impulse Test (vHIT)
    Time Frame
    Baseline, three and six months
    Title
    Gait analysis
    Description
    Changes in gait quality regarding balance using a motion tracker
    Time Frame
    Baseline, three and six months
    Title
    Orthostatic blood pressure
    Description
    Changes in orthostatic blood pressure measured from lying to standing and every minute for five minutes
    Time Frame
    Baseline, three and six months
    Title
    Body composition
    Description
    Changes in body composition using bioimpedance
    Time Frame
    Baseline, three and six months
    Title
    Muscle quality
    Description
    Changes in muscle quality using muscle biopsy
    Time Frame
    Baseline and three months
    Title
    Muscle quality
    Description
    Changes in muscle quality using ultrasound
    Time Frame
    Baseline and three months
    Title
    Frailty
    Description
    Presence of frailty using Geriatric-8 (G8)
    Time Frame
    Baseline
    Title
    Frailty
    Description
    Presence of frailty using Clinical Frailty Scale (CFS)
    Time Frame
    Baseline
    Title
    Activity level
    Description
    Description of activity level using activity tracker
    Time Frame
    Baseline and three months
    Title
    Cessation of chemotherapy
    Description
    Description of cessation of chemotherapy
    Time Frame
    After 6, 12, and 24 weeks (from baseline)
    Title
    Exercise habits
    Description
    Recording of exercise habits
    Time Frame
    Follow-up at 1, 2, 3, and 5 years
    Title
    Overall survival
    Description
    Recording of overall survival
    Time Frame
    Follow-up at 1, 2, 3, and 5 years
    Title
    Hospitalisations
    Description
    Recording of hospitalisations
    Time Frame
    Follow-up at 1, 2, 3, and 5 years
    Title
    Progression of cancer
    Description
    Recording of progression of cancer
    Time Frame
    Follow-up at 1, 2, 3, and 5 years
    Title
    Recurrence of cancer
    Description
    Recording of recurrence of cancer
    Time Frame
    Follow-up at 1, 2, 3, and 5 years

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Meet the criteria of the oncological departments of receiving adjuvant chemotherapy or first line palliative chemotherapy for colorectal cancer ≥65 years of age at the time of signing the informed consent form Able to speak and read Danish, and to provide a signed informed consent form Have an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2 Exclusion Criteria: Other malignant disease except from basal cell carcinoma and carcinoma in situ cervices uteri within five years Have recieved chemotherapy within five years Severe physical disability that hinders physical exercise Dementia, psychotic disorders, or other cognitive diseases or conditions that hinder participation in a clinical exercise-based trial Inability to sign informed content Patients who have had a consultation in the geriatric outpatient clinic within the past six months
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Katrine S Piper, Msc
    Email
    katrine.storm.piper@regionh.dk
    First Name & Middle Initial & Last Name or Official Title & Degree
    Jan Christensen, PhD
    Email
    jan.christensen.02@regionh.dk

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    On reasonable request

    Learn more about this trial

    The SaVe Project-Sarcopenia and Vertigo in Aging Patients With Colorectal Cancer

    We'll reach out to this number within 24 hrs